Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.

ABSTRACT:

Objectives

This study aims to retrospectively assess C-lectin-like molecule 1 (CLL-1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL-1 bimodal associations with leukemia and patient-specific characteristics.

Methods

Flow cytometry assays were performed to assess the deeper immunophenotyping of CLL-1 bimodality. Cytogenetic analysis was performed to characterize the gene mutation on CLL-1-negative subpopulation of CLL-1 bimodal AML samples.

Results

The frequency of a bimodal pattern of CLL-1 expression of CD34⁺ blasts ranged from 8% to 65% in the different cohorts. Bimodal CLL-1 expression was most prevalent in patients with MDS-related AML (P = .011), ELN adverse risk (P = .002), NPM1 wi

SUBMITTER: Ngai LL 

PROVIDER: S-EPMC8457079 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature